Zytiga ( abiraterone acetate) received expanded use approval to treat men with advanced prostate cancer last week. In addition to extending lives, a new study has found Zytiga also keeps men feeling better during their journey.

When blood has gone bad, patients turn normally to donors for help. But using undefined stem cells from other parts of the patient's body may help donors become more of a last-minute option in the future.

Some say it's 30 minutes of exercise twice or thrice weekly to see benefits. Others say it's 20 minutes done more often. For cancer patients who may be short on time or lack the energy, just a few minutes a day can help.

Having a family history of any kind of cancer isn’t a bright spot for your own odds. It’s just part of nature over which we have no control. In terms of colorectal cancer, new understandings may help avoid a nightmare journey.

Teenage girls have been targets of HPV campaigns over the last several years. But older women should be the focus as well, especially as repeat cases pop up in those already infected.

Doctors can talk to patients until they are blue in the face, but sometimes a short video can convey the clearest message. End-stage cancer patients may benefit from video learning.

If you’re reading this article, chances are you have a healthier attitude about cancer prevention. That is, you don’t link cancer with luck and/or fate. In other words, you're not a fatalistic about cancer.

Stomach cancer is not one disease, but many. Understanding the different types of this complex cancer could lead to improved treatments.

Folks living with two types of blood cancer have new choices as of today. The US Food and Drug Administration has approved Iclusig ( ponatinib ) to treat chronic myeloid leukemia ( CML ) and Philadelphia chromosome-positive acute lymphoblastic leukemia ( Ph + ALL). 

Men with metastatic prostate cancer may have a new treatment.  Radium-223 dichloride (radium-223) is designed to treat castration-resistant prostate cancer that has spread to the bone.